SCI时时刷

search
+
Volume 26 Author Index
Volume 26 Author Index
A Aakhus, Erin, 630–634 Aapro, Matti, e1073–e1082 Aarne, Valerie,...
Antibiotics and Adverse Events in Patients with Pancreatic Cancer Treated with Gemcitabine: Looking for Novel Clinical and Preclinical Insights
Antibiotics and Adverse Events in Patients with Pancreatic Cancer Treated with Gemcitabine: Looking for Novel Clinical and Preclinical Insights
This letter to the editor remarks on a recently published article reporting on gemcitabine-related adverse events associat...
Immunotherapy for Metastatic Non‐Small Cell Lung Cancer: Real‐World Data from an Academic Central and Eastern European Center
Immunotherapy for Metastatic Non‐Small Cell Lung Cancer: Real‐World Data from an Academic Central and Eastern European Center
Abstract Background Immunotherapy with immune checkpoint inhibitors (ICIs) recently became the standard treatment for pati...
Transitions
Transitions
Marty and Ann Murphy, co-founders of AlphaMed Press, publisher of The Oncologist, will be retiring from this publication a...
COVID‐19 Pandemic and Cancer: The Importance of Early Palliative Care
COVID‐19 Pandemic and Cancer: The Importance of Early Palliative Care
In terms of clinical and ethical situations, this narrative compares the COVID-19 pandemic to the cancer endemic and share...
Validation of a Circulating Tumor DNA‐Based Next‐Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing
Validation of a Circulating Tumor DNA‐Based Next‐Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing
Abstract Background Characterization of circulating tumor DNA (ctDNA) has been integrated into clinical practice. Although...
BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1‐Rearranged Non‐Small Cell Lung Cancer: A Case Report
BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1‐Rearranged Non‐Small Cell Lung Cancer: A Case Report
Abstract Crizotinib, a multitargeted MET/ALK/ROS1 tyrosine kinase inhibitor, has been approved for the treatment of ROS1 f...
Remembering Joe
Remembering Joe
My dear friend and mentor, Joseph R. Bertino, M.D., died Sunday, October 10, 2021 in New Brunswick, New Jersey, after an e...
Effect of a Skills Training for Oncologists and a Patient Communication Aid on Shared Decision Making About Palliative Systemic Treatment: A Randomized Clinical Trial
Effect of a Skills Training for Oncologists and a Patient Communication Aid on Shared Decision Making About Palliative Systemic Treatment: A Randomized Clinical Trial
The Oncologist 2020;25:e578–e588; first published on November 26, 2019; doi: 10.1634/theoncologist.2019-0453 ...
Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center
Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center
Abstract Background Trifluridine/tipiracil (FTD/TPI) and regorafenib prolong survival for patients with refractory metasta...
Patient‐Reported Outcomes with Selpercatinib Among Patients with RET Fusion–Positive Non‐Small Cell Lung Cancer in the Phase I/II LIBRETTO‐001 Trial
Patient‐Reported Outcomes with Selpercatinib Among Patients with RET Fusion–Positive Non‐Small Cell Lung Cancer in the Phase I/II LIBRETTO‐001 Trial
Abstract Background LIBRETTO-001 is an ongoing, global, open-label, phase I/II study of selpercatinib in patients with adv...
Patient‐Reported Outcomes with Selpercatinib Treatment Among Patients with RET‐Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO‐001 Trial
Patient‐Reported Outcomes with Selpercatinib Treatment Among Patients with RET‐Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO‐001 Trial
Abstract Background Medullary thyroid cancer (MTC) standard of care includes multikinase inhibitors (MKIs), which can exac...
Adherence to Endocrine Therapy and Racial Outcome Disparities in Breast Cancer
Adherence to Endocrine Therapy and Racial Outcome Disparities in Breast Cancer
Abstract The disparity in outcomes of breast cancer for Black compared with White women in the U.S. is well known and pers...
Assessment of PD‐L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Patients with Cancer Receiving PD‐1/PD‐L1 Blockade Therapies
Assessment of PD‐L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Patients with Cancer Receiving PD‐1/PD‐L1 Blockade Therapies
Abstract Background Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade immunotherapies have changed ...
Longitudinal Assessment of Prognostic Understanding in Patients with Advanced Lung Cancer and Its Association with Their Psychological Distress
Longitudinal Assessment of Prognostic Understanding in Patients with Advanced Lung Cancer and Its Association with Their Psychological Distress
Abstract Background Accurate prognostic understanding in patients with advanced cancer is essential for shared decision ma...
Treatment Patterns and Outcomes of Women with Symptomatic and Asymptomatic Breast Cancer Brain Metastases: A Single‐Center Retrospective Study
Treatment Patterns and Outcomes of Women with Symptomatic and Asymptomatic Breast Cancer Brain Metastases: A Single‐Center Retrospective Study
Abstract Background Breast cancer is the most common cancer among women worldwide and the second leading cause of brain me...
Risk Stratification of Early‐Stage Cervical Cancer with Intermediate‐Risk Factors: Model Development and Validation Based on Machine Learning Algorithm
Risk Stratification of Early‐Stage Cervical Cancer with Intermediate‐Risk Factors: Model Development and Validation Based on Machine Learning Algorithm
Abstract Background Adjuvant therapy for patients with cervical cancer (CC) with intermediate-risk factors remains controv...
Patient‐Reported Outcomes with Selpercatinib Among Patients with RET Fusion‐Positive Non‐small Cell Lung Cancer in the Phase 1/2 LIBRETTO‐001 Trial
Patient‐Reported Outcomes with Selpercatinib Among Patients with RET Fusion‐Positive Non‐small Cell Lung Cancer in the Phase 1/2 LIBRETTO‐001 Trial
Abstract Background LIBRETTO-001 is an ongoing, global, open-label, phase 1/2 study of selpercatinib in patients with adva...
Patient‐Reported Outcomes with Selpercatinib Treatment Among Patients with RET‐Mutant Medullary Thyroid Cancer in the Phase 1/2 LIBRETTO‐001Trial
Patient‐Reported Outcomes with Selpercatinib Treatment Among Patients with RET‐Mutant Medullary Thyroid Cancer in the Phase 1/2 LIBRETTO‐001Trial
ABSTRACT Background Medullary thyroid cancer (MTC) standard of care includes multikinase inhibitors (MKIs), which can exac...
Quality of Life Associated with Nausea and Vomiting from Anthracycline‐Based Chemotherapy: A Pooled Data Analysis from Three Prospective Trials
Quality of Life Associated with Nausea and Vomiting from Anthracycline‐Based Chemotherapy: A Pooled Data Analysis from Three Prospective Trials
Abstract Background There is limited work on the impact of CINV on Quality of Life (QoL) in Adriamycin-Cyclophosphamide (A...
BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1‐rearranged NSCLC: a Case Report
BRAF V600E Mediates Crizotinib Resistance and Responds to Dabrafenib and Trametinib in a ROS1‐rearranged NSCLC: a Case Report
Abstract Crizotinib, a multi-targeted MET/ALK/ROS1 tyrosine kinase inhibitor, has been approved for the treatment of ROS1 ...
Increased Risk for Ipsilateral Breast Tumor Recurrence in Invasive Lobular Carcinoma after Accelerated Partial Breast Irradiation Brachytherapy
Increased Risk for Ipsilateral Breast Tumor Recurrence in Invasive Lobular Carcinoma after Accelerated Partial Breast Irradiation Brachytherapy
Abstract Background The suitability criteria for accelerated partial breast irradiation (APBI) from the American Brachythe...
Assessment of PD‐L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Cancer Patients Receiving PD‐1/PD‐L1 Blockade Therapies
Assessment of PD‐L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Cancer Patients Receiving PD‐1/PD‐L1 Blockade Therapies
Abstract Background PD-1/PD-L1 blockade immunotherapies have changed the landscape of cancer therapy. However, the main li...
The Relationship Between Frailty and Emotional Health in Older Patients with Advanced Cancer
The Relationship Between Frailty and Emotional Health in Older Patients with Advanced Cancer
Abstract Background Aging-related deficits that eventually manifest as frailty may be associated with poor emotional healt...
Changes in cancer patients’ and caregivers’ disease perceptions while receiving early palliative care: a qualitative and quantitative analysis
Changes in cancer patients’ and caregivers’ disease perceptions while receiving early palliative care: a qualitative and quantitative analysis
Abstract Background Little is known about underlying mechanisms through which early palliative care (EPC) improves multipl...
Longitudinal Assessment of Prognostic Understanding in Advanced Lung Cancer Patients and Its Association with Their Psychological Distress
Longitudinal Assessment of Prognostic Understanding in Advanced Lung Cancer Patients and Its Association with Their Psychological Distress
Abstract Background Accurate prognostic understanding in advanced cancer patients is essential for shared decision making;...
Physician Interpretation of Data of Uncertain Clinical Utility in Oncology Prescription Drug Promotion
Physician Interpretation of Data of Uncertain Clinical Utility in Oncology Prescription Drug Promotion
Abstract Background Little is known about how physicians interpret data displays that depict preliminary or exploratory cl...
First‐Line Durvalumab in Addition to Etoposide and Platinum for Extensive‐Stage Small Cell Lung Cancer: A U.S.‐Based Cost‐Effectiveness Analysis
First‐Line Durvalumab in Addition to Etoposide and Platinum for Extensive‐Stage Small Cell Lung Cancer: A U.S.‐Based Cost‐Effectiveness Analysis
Abstract Background The latest published CASPIAN trial demonstrated that adding durvalumab to etoposide and platinum (EP) ...
Successful Treatment of Afatinib Reversing Epidermal Growth Factor Receptor Exon19Deletion/G724S Mutation Resistance Guided by Protein‐Drug Docking
Successful Treatment of Afatinib Reversing Epidermal Growth Factor Receptor Exon19Deletion/G724S Mutation Resistance Guided by Protein‐Drug Docking
Abstract G724S is a rare mutation induced by different generations of tyrosine kinase inhibitors (TKIs). No clinical effec...
Tyrosine Kinase Inhibitors and Vascular Adverse Events in Patients with Chronic Myeloid Leukemia: A Population‐Based, Propensity Score‐Matched Cohort Study
Tyrosine Kinase Inhibitors and Vascular Adverse Events in Patients with Chronic Myeloid Leukemia: A Population‐Based, Propensity Score‐Matched Cohort Study
Abstract Background Tyrosine kinase inhibitors (TKIs) have shown long-term survival benefits in patients with chronic myel...
阅读更多
format_indent_increase